Belgium, Mont Saint-Guibert, 13 January 2026 – Cellistic, a global leader in allogeneic iPSC-derived cell therapy manufacturing, today announced the launch of three new iPSC-derived GMP cell therapy manufacturing platforms: Echo™-T, Echo™-Cardio, and Echo™-Endothelial. The new platforms are designed to advance cell therapies and drive progress across immuno-oncology and regenerative medicine.Building on the success of the Cellistic Echo™-NK manufacturing platform for natural killer (NK) cells, the expanded Cellistic Echo™ portfolio leverages the company’s GMP manufacturing expertise and its EMA-certified, FDA- and PMDA-compliant manufacturing facility. Through dedicated platform development, these capabilities are extended to deliver scalable solutions across additional immune and regenerative cell types.
[Read more…]
WORD+2026 Connecting Global NAM Research. #Bettertogether Organoids, Organ-on-a-Chip, Assembloids and innovative NAMS.
In just three weeks time, the 5th WORD+ event brings together leading researchers, societies and technologies in Cambridge, U.K. February 4th and 5th sees over 40 research talks from academia, pharmaceutical & industry. Uniquely open, fun and collaborative, prices are supported for researchers to attend. See all chairs and speakers here [Read more…]
TheWell Bioscience and PeptiGrowth Enter into Marketing Collaboration Agreement to Advance Next-Generation Cell Culture Solutions
Monmouth Junction, NJ and Tokyo, Japan — January 7, 2026 — TheWell Bioscience Inc., a biotechnology company pioneering next-generation animal-free biofunctional hydrogels, and PeptiGrowth Inc., a leader in innovative synthetic peptide growth factors, today announced that the two companies have entered into a Marketing Collaboration Agreement to jointly promote cutting-edge solutions for stem cell culture, organoid development, and cell therapy manufacturing. [Read more…]
PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: IL-15 alternative peptide
January 6, 2026, Chiyoda-ku, Tokyo — PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jun Minamitani) has successfully developed a novel synthetic peptide called “IL-15 alternative peptide” which is functionally equivalent to recombinant interleukin 15 (IL-15). This product will be on the market in December 2025. [Read more…]
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL:
A Cost-Optimized Approach
Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing services that support robust regulatory pathways without compromising quality or operational discipline. Through our European partnership with Histocell and its EMA-authorized facility in Bilbao, Spain, together with REPROCELL’s U.S. GMP site in Beltsville, Maryland, we offer a dual-site manufacturing network aligned with FDA, EMA, and PMDA expectations.
This infrastructure provides the scale, regulatory alignment, and global flexibility needed for allogeneic therapy programs moving to clinical translation without the excessive costs often linked to iPSC GMP manufacturing. [Read more…]
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 18
- Next Page »